Swab both nostrils using medium pressure. Insert the swab approximately 1/2″-3/4″ (no deeper) and make at least 5 circles, swabbing the inner sides of each nostril. Take approximately 15 seconds per nostril.
The ASSURE-100 Rapid COVID-19 Home Test provides accurate and reliable results in just 20 minutes using a shallow nasal swab for better comfort.
The test was developed by Oceanit, a Hawai'i-based technology company of just 200 people. Oceanit was successfully granted two FDA Authorizations for the ASSURE-100 Rapid COVID-19 Test, enabling it to be used by health care professionals around the world, and at home without a prescription.
Founded in 1985 in Honolulu, Hawai'i, Oceanit has earned a world-class reputation for breakthrough science & technology, sustainable engineering, and disruptive innovation built upon our values of Curiosity, Community, and Ohana. We are a skilled group of scientists, engineers, innovators, and entrepreneurs who solve the world's most difficult problems.
Oceanit Foundry LLC is a subsidiary company of Oceanit Labs, Inc.
The ASSURE-100 Rapid COVID-19 Home Test was designed by scientists and engineers in Honolulu, bringing a world-class diagnostic tool from Hawaii to the rest of the world.
The ASSURE-100 Rapid COVID-19 Test was developed by Oceanit in the USA, and was granted two U.S. Food & Drug Administration Emergency Use Authorizations in 2022: 1. for point of care, and 2. for at-home (OTC) use. Oceanit is a Hawaii-based technology company that is concerned with protecting our communities from current and future COVID outbreaks.
ASSURE-100 rapid tests are available for purchase online and for local Hawai'i delivery or pickup. For bulk ordering, please contact us by clicking on the button below.
For use under FDA Emergency Use Authorization (EUA) only.
New variants have shown that anyone can be vulnerable to COVID-19, even the young and the vaccinated. Early and frequent testing helps protect friends, family, and the community from potential exposure. With the ASSURE-100 Rapid COVID-19 Home Test, you can quickly and conveniently test yourself from the convenience of your home.
The ASSURE-100 Rapid COVID-19 Home Test provides accurate and reliable results in just 20 minutes using a lower nasal swab for better comfort.
For use under FDA Emergency Use Authorization (EUA) only.
The ASSURE Integrated Care Platform delivers a fast, accurate, and scalable solution for organizations of every type and size, from business to the public sector, schools, and more. Whether testing on-site or in employee homes, the simplicity of the ASSURE Rapid COVID-19 tests makes frequent, accurate testing seamless and intuitive, while the lower nasal swab makes it a more comfortable experience.
The ASSURE-100 Rapid COVID-19 Rapid Test is simple and intuitive, containing just three elements: the nasal swab, solution vial, and test cassette.
For use under FDA Emergency Use Authorization (EUA) only.
Keep your loved ones and community safe with Simple, Fast and Accurate testing.
Frequently asked questions to help you learn more about ASSURE rapid tests.
ASSURE-100 is a rapid COVID-19 test that uses an anterior nasal specimen to detect COVID-19, the disease caused by the SARS-CoV-2 virus. ASSURE is an acronym for: Accelerated Sensor Solution for Urgent Response to Epidemics.
The ASSURE technology and ASSURE-100 rapid COVID-19 test was developed by Oceanit in Hawaiʻi and was put through testing and clinical trials in Hawaii and in other states across the US.
ASSURE-100 uses shallow nasal specimens to detect COVID-19 using a lateral flow assay (LFA) test cassette. A shallow anterior nasal swab specimen is mixed with buffer solution and then poured into the well on the test cassette. ASSURE tests are visually read, and do not require an external device to interpret results.
Yes, the ASSURE-100 Rapid COVID-19 Home Test clinical trial included BA.2.12.1 and BA.2 variant samples. Additionally, the ASSURE-100 test was evaluated in a dilution series of clinical specimens positive for the Omicron variants BA.5 and BE.1. This testing was conducted by National Institutes of Health (NIH) as a component of the Rapid Acceleration of Diagnostics (RADx) initiative. Results indicate that ASSURE-100 detects both BA.5 and BE.1 variants.
Results should be read at 20 minutes.
If you have any questions please contact us at info@assure-test.com or by clicking the button below. Alternatively, you can get in touch by filling the contact form.